|
May 22
|
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
|
|
May 16
|
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
|
|
May 13
|
Why Is Inventiva's Stock Trading Higher on Monday?
|
|
May 13
|
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
|
|
Jan 10
|
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
|